Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

Yale University logo

Yale University

Status

Completed

Conditions

Opiate Dependence
Cocaine Dependence

Treatments

Diagnostic Test: 11UCB-J PET Scan

Study type

Interventional

Funder types

Other

Identifiers

NCT03527485
2000021843

Details and patient eligibility

About

This study aims to measure synaptic density in the brains (including in ventral striatum \[VS\] and medial prefrontal cortex \[mPFC\]) of abstinent subjects with Cocaine Use Disorder (CUD) or Opiate Use Disorder (OUD) as compared to healthy control (HC) subjects using 11C-UCB-J PET. Subjects will undergo a single 11C-UCB-J (also known as 11C-APP311) PET scan. This would be the very first to image synaptic density in human cocaine and opiate users, thereby testing whether altered synaptic density in the rodent brain is recapitulated in CUD and OUD humans. If confirmed, the current study would provide compelling clinical-translational support for an important pathophysiological mechanism of addiction - aberrant structural synaptic plasticity. As such, the current study has considerable potential for advancing the neurobiological understanding of human cocaine and opiate addiction.

Enrollment

15 patients

Sex

All

Ages

21 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 21-55 years;
  • Voluntary, written, informed consent;
  • Physically healthy by medical history, physical, neurological, ECG and laboratory examinations;
  • DSM-5 criteria for Cocaine Use Disorder or Opiate Use Disorder;
  • Documented evidence (by urine toxicology) of 2 weeks abstinence from cocaine and 4 weeks abstinence from opiates;
  • For females, a negative serum pregnancy (HCG) test;
  • Full scale and verbal IQs > 80 (Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV)).

Exclusion criteria

  • A history of other substance dependence (e.g., alcohol, sedative hypnotics), except for nicotine;
  • A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5);
  • A history of significant and uncontrolled medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular, seizures, traumatic brain injury) illness;
  • A history of seizures;
  • Current use of psychotropic and/or potentially psychoactive prescription medications;
  • Medical contraindications to participation in a magnetic resonance (MR) imaging procedure (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.) as recorded on the MR safety sheet;
  • For females, physical or laboratory (HCG) evidence of pregnancy;
  • PTT and PT/INR lab results not appropriate for arterial line placement;
  • Taking anticoagulants;
  • Being prescribed methadone/buprenorphine upon screening.

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

15 participants in 3 patient groups

Opiate Use Disorder (OUD)
Other group
Description:
30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
Treatment:
Diagnostic Test: 11UCB-J PET Scan
Cocaine Use Disorder (CUD)
Other group
Description:
30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
Treatment:
Diagnostic Test: 11UCB-J PET Scan
Healthy Controls (HC)
Other group
Description:
30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
Treatment:
Diagnostic Test: 11UCB-J PET Scan

Trial contacts and locations

1

Loading...

Central trial contact

Marcella Mignosa, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems